Edition:
United States

Mesoblast Ltd (MSB.AX)

MSB.AX on Australia Stock Exchange

1.28AUD
22 Nov 2017
Change (% chg)

-- (--)
Prev Close
$1.28
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,742,535
52-wk High
$3.41
52-wk Low
$1.17

Select another date:

Fri, Nov 10 2017

BRIEF-MESOBLAST PHASE 2 TRIAL RESULTS SHOW DURABLE EFFECTS IN ARTHRITIS PATIENTS

* MESOBLAST PHASE 2 TRIAL RESULTS SHOW EARLY AND DURABLE EFFECTS OF SINGLE MESENCHYMAL PRECURSOR CELL INFUSION IN BIOLOGIC REFRACTORY RHEUMATOID ARTHRITIS PATIENTS

BRIEF-Clinical trial of Mesoblast’S cell therapy in end-stage heart failure patients completes enrollment

* Clinical trial of Mesoblast’S cell therapy in end-stage heart failure patients completes enrollment Source text for Eikon: Further company coverage:

BRIEF-Mesoblast posts FY loss attributable of $76.8 mln

* FY loss attributable to owners of co $76.8 million versus loss of $4.1 million Source text for Eikon: Further company coverage:

BRIEF-Mesoblast completes institutional entitlement offer for capital raise

* Completes institutional entitlement offer for fully underwritten A$50.7 million capital raise

BRIEF-Mesoblast announces capital raising

* Fully underwritten accelerated non-renounceable entitlement offer to raise A$50.7m

BRIEF-Mesoblast seeks trading halt

* Seeking trading halt pending an announcement to ASX by company regarding a fully underwritten capital raising Source text for Eikon: Further company coverage:

BRIEF-Mesoblast Ltd files ‍​for $180 million American depositary shares representing ordinary shares

* Mesoblast Ltd - files ‍​for $180 million American depositary shares representing ordinary shares Source text: (http://bit.ly/2u50ziE) Further company coverage:

UPDATE 1-Australia's Mesoblast posts narrower quarterly loss, rise in R&D costs

May 25 Australian regenerative medicine maker Mesoblast Ltd on Thursday posted a narrower quarterly loss but booked a rise in research and development costs.

CORRECTED-Australia's Mesoblast flags "going concern" doubts

May 25 Australian regenerative medicine maker Mesoblast Ltd said on Thursday it needed new funding from a third party partner or from capital raising to continue in business as it had cash reserves of $69.1 million.

Select another date: